Remegen Co. Ltd. emerged as a surprise challenger in the generalized myasthenia gravis space, unveiling positive phase III data of its China-approved lupus drug, telitacicept (RCT-18; Tai’ai), in the ...

(CNN) — The Department of Homeland Security and the Internal Revenue Service finalized an agreement Monday to provide sensitive taxpayer data to federal immigration authorities as part of ...

– Data support continued advancement to the clinic, with IND submission planned in 2025 BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for ...

Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in ...

Visitors must ensure the items they bring are clean. In our new research, we analysed a century of data on how many species have been introduced to the icy continent and surrounding sub-Antarctic ...

The presentation includes new preclinical data with the company's lead drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer's disease. The presentation, titled ...

Visitors must ensure the items they bring are clean. In our new research, we analysed a century of data on how many species have been introduced to the icy continent and surrounding sub-Antarctic ...

frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen> The reason ...

We are encouraged to see these positive data that build on that legacy and show how PALYNZIQ can make an impact for adolescents as they begin their transition to adult living,” said Greg Friberg, M.D.

We are encouraged to see these positive data that build on that legacy and show how PALYNZIQ can make an impact for adolescents as they begin their transition to adult living," said Greg Friberg ...

(RTTNews) - INmune Bio, Inc. (INMB), a clinical-stage immunology ... CDR-SB), reinforcing its validity. Preliminary data showed 69.2% of participants carried the APOE e4 allele, and 64.4% had ...